ATE505472T1 - Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen - Google Patents

Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen

Info

Publication number
ATE505472T1
ATE505472T1 AT06777183T AT06777183T ATE505472T1 AT E505472 T1 ATE505472 T1 AT E505472T1 AT 06777183 T AT06777183 T AT 06777183T AT 06777183 T AT06777183 T AT 06777183T AT E505472 T1 ATE505472 T1 AT E505472T1
Authority
AT
Austria
Prior art keywords
treatment
pyridine derivatives
psychotic diseases
psychotic
diseases
Prior art date
Application number
AT06777183T
Other languages
English (en)
Inventor
Giuseppe Alvaro
Daniele Andreotti
Sandro Belvedere
Fabio Romano Di
Alessandro Falchi
Riccardo Giovannini
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0518472A external-priority patent/GB0518472D0/en
Priority claimed from GB0611153A external-priority patent/GB0611153D0/en
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of ATE505472T1 publication Critical patent/ATE505472T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
AT06777183T 2005-09-09 2006-09-07 Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen ATE505472T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0518472A GB0518472D0 (en) 2005-09-09 2005-09-09 Novel compounds
GB0611153A GB0611153D0 (en) 2006-06-06 2006-06-06 Novel compounds
PCT/EP2006/008845 WO2007028654A1 (en) 2005-09-09 2006-09-07 Pyridine derivatives and their use in the treatment of psychotic disorders

Publications (1)

Publication Number Publication Date
ATE505472T1 true ATE505472T1 (de) 2011-04-15

Family

ID=37546936

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06777183T ATE505472T1 (de) 2005-09-09 2006-09-07 Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen

Country Status (27)

Country Link
US (3) US7683056B2 (de)
EP (2) EP2336136A1 (de)
JP (1) JP5121716B2 (de)
KR (1) KR101292348B1 (de)
AR (1) AR058805A1 (de)
AT (1) ATE505472T1 (de)
AU (1) AU2006289281B2 (de)
BR (1) BRPI0615787B8 (de)
CA (1) CA2621564C (de)
CR (1) CR9847A (de)
CY (1) CY1111907T1 (de)
DE (1) DE602006021323D1 (de)
DK (1) DK1928886T3 (de)
EA (1) EA013909B1 (de)
HR (1) HRP20110457T1 (de)
IL (1) IL189578A (de)
JO (1) JO2722B1 (de)
MA (1) MA29780B1 (de)
MY (1) MY145713A (de)
NO (1) NO340921B1 (de)
NZ (1) NZ565983A (de)
PE (1) PE20070614A1 (de)
PL (1) PL1928886T3 (de)
PT (1) PT1928886E (de)
SI (1) SI1928886T1 (de)
TW (1) TWI378101B (de)
WO (1) WO2007028654A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039123A2 (en) * 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
EP1943216B1 (de) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamidderivate als natriumkanalmodulatoren
SI2404919T1 (sl) 2005-11-08 2013-12-31 Vertex Pharmaceuticals Incorporated Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CA2676357A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
WO2008135826A2 (en) 2007-05-03 2008-11-13 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
CA2686838C (en) 2007-05-09 2017-03-14 Vertex Pharmaceuticals Incorporated Modulators of cftr
PT2639222T (pt) 2007-12-07 2016-11-01 Vertex Pharma Processo de produção de ácidos cicloalquilcarboxamido-piridina-benzoicos
CA2706920C (en) 2007-12-07 2018-02-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2098526B1 (de) * 2008-02-22 2014-01-15 Neurotune AG Stickstoffhaltige bizyklische Verbindungen, die aktiv für chronische Schmerzzustände sind
ES2647531T3 (es) 2008-02-28 2017-12-22 Vertex Pharmaceuticals Incorporated Derivados de heteroarilo como moduladores de CFTR
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
WO2009119528A1 (ja) * 2008-03-24 2009-10-01 武田薬品工業株式会社 複素環化合物
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
EP2145891A1 (de) 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substierte 5-Carboxy-Oxadiazin-Chinolon-Derivate, ihre Herstellung und ihre Anwendung als antibakterielle Mittel
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
TW201109335A (en) 2009-08-04 2011-03-16 Takeda Pharmaceutical Heterocyclic compounds
AU2010288502B2 (en) * 2009-08-27 2013-12-12 KaNDy Therapeutics Ltd. Anhydrate forms of a pyridine derivative
WO2011054773A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Novel lactam compounds
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
US9115132B2 (en) 2010-07-09 2015-08-25 Convergence Pharmaceuticals Limited Tetrazole compounds as calcium channel blockers
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
WO2013049174A1 (en) 2011-09-29 2013-04-04 Abbvie Inc. Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers
US8669255B2 (en) 2011-09-29 2014-03-11 Abbvie Inc. Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers
WO2014093337A1 (en) 2012-12-12 2014-06-19 Abbvie, Inc. Diazepine derivatives useful as calcium channel blockers in the treatment of pain
WO2015068744A1 (ja) 2013-11-08 2015-05-14 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
PL3068392T3 (pl) 2013-11-12 2021-07-19 Vertex Pharmaceuticals Incorporated Proces wytwarzania kompozycji farmaceutycznych do leczenia chorób, w których pośredniczy cftr
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
JP6609253B2 (ja) * 2014-08-06 2019-11-20 キッセイ薬品工業株式会社 シアノチオフェン誘導体
JP6494757B2 (ja) 2014-11-18 2019-04-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ハイスループット試験高速液体クロマトグラフィーを行うプロセス
WO2016102967A1 (en) 2014-12-23 2016-06-30 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
PT3297631T (pt) * 2015-05-18 2019-10-10 Nerre Therapeutics Ltd Receptor nk-1/nk-3 antagonista para o tratamento de afrontamentos
KR20200061381A (ko) 2017-10-05 2020-06-02 바이오젠 인크. 알파-카르복스아미드 피롤리딘 유도체를 제조하기 위한 공정
IL276959B1 (en) 2018-03-14 2024-03-01 Kandy Therapeutics Ltd A new pharmaceutical formulation containing dual NK-1/NK-3 receptor antagonists
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
IL292921A (en) 2019-11-15 2022-07-01 Kandy Therapeutics Ltd A new chemical process for the preparation of 6-chloro-4-(4-fluoro-2-methylphenyl)pyridine-3-amine a key intermediate of nt-814
WO2021261969A1 (ko) * 2020-06-26 2021-12-30 홀로스메딕 주식회사 신규한 화합물의 제조방법
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
US20240115539A1 (en) * 2021-04-05 2024-04-11 The Board Of Trustees Of The Leland Stanford Junior University Enantiomer selective action on neurotransmission

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921855A (en) 1987-06-22 1990-05-01 Fujisawa Pharmaceutical Co., Ltd. New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same
US5166203A (en) 1990-08-30 1992-11-24 Kanebo, Ltd. Quinolinecarboxylic acid derivatives, antibacterial agent containing the same
SI1004583T1 (en) 1998-11-23 2004-12-31 Pfizer Products Inc. Process and hydantoin intermediates for the synthesis of growth hormone secretagogues
DK1394150T3 (da) 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
CO5261615A1 (es) 1999-12-01 2003-03-31 Agouron Pharma Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
WO2005002577A1 (en) 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia

Also Published As

Publication number Publication date
EA200800784A1 (ru) 2008-06-30
JP2009507801A (ja) 2009-02-26
US20100152175A1 (en) 2010-06-17
US7919491B2 (en) 2011-04-05
IL189578A (en) 2015-10-29
US7683056B2 (en) 2010-03-23
DK1928886T3 (da) 2011-07-11
IL189578A0 (en) 2008-08-07
KR20080046232A (ko) 2008-05-26
CY1111907T1 (el) 2015-11-04
KR101292348B1 (ko) 2013-09-09
CA2621564A1 (en) 2007-03-15
AR058805A1 (es) 2008-02-27
NZ565983A (en) 2011-04-29
SI1928886T1 (sl) 2011-08-31
AU2006289281B2 (en) 2012-05-17
BRPI0615787A2 (pt) 2009-06-16
PE20070614A1 (es) 2007-08-02
CR9847A (es) 2008-07-29
EP1928886A1 (de) 2008-06-11
AU2006289281A1 (en) 2007-03-15
NO20081728L (no) 2008-04-07
MA29780B1 (fr) 2008-09-01
WO2007028654A1 (en) 2007-03-15
US8097618B2 (en) 2012-01-17
US20080269208A1 (en) 2008-10-30
EA013909B1 (ru) 2010-08-30
CA2621564C (en) 2014-06-03
DE602006021323D1 (de) 2011-05-26
PL1928886T3 (pl) 2011-09-30
BRPI0615787B8 (pt) 2021-05-25
JO2722B1 (en) 2013-09-15
US20110190276A1 (en) 2011-08-04
HRP20110457T1 (hr) 2011-07-31
PT1928886E (pt) 2011-07-14
MY145713A (en) 2012-03-30
TW200804401A (en) 2008-01-16
BRPI0615787B1 (pt) 2020-08-11
JP5121716B2 (ja) 2013-01-16
EP2336136A1 (de) 2011-06-22
TWI378101B (en) 2012-12-01
EP1928886B1 (de) 2011-04-13
NO340921B1 (no) 2017-07-17

Similar Documents

Publication Publication Date Title
ATE505472T1 (de) Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen
ATE448206T1 (de) Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen
DE502005007427D1 (de) 3-aminoindazole derivate und ihre verwendung zur behandlung sgk-bedingten krankheiten
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE530553T1 (de) Zytotoxische mittel mit neuen tomamycin-derivaten und ihre therapeutische verwendung
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602005016890D1 (de) Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
IS8134A (is) Píperasínafleiður og notkun þeirra til að meðhöndla tauga- og geðsjúkdóma
DE502005003904D1 (de) Tetrahydrobenzo (d) azepin-2-on derivate und ihre verwendung zur behandlung von kardiovaskulären krankheiten
NO20055588D0 (no) Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
IL183827A0 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
ATE479437T1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
ATE459608T1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
ATE420081T1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
ATE489091T1 (de) Dha-ester und ihre verwendung bei der behandlung und der prävention von kardiovaskulären erkrankungen
ATE475661T1 (de) Triazolopyridin-carboxamid-derivate sowie ihre herstellung und therapeutische verwendung
IS7444A (is) Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
ATE427748T1 (de) Pyridin-derivate und ihre verwendung als urotensin ii antagonisten
SI1831227T1 (sl) Nove heterociklične spojine uporabne za zdravljenje vnetnih in alergijskih motenj
ATE448211T1 (de) 1,2,4-triazinderivate, ihre herstellung und ihre verwendung in der humantherapie
ATE405565T1 (de) Herstellung von 6-substituierten pyridoindolon- derivaten und ihre therapeutische verwendung
ATE388145T1 (de) Imidazol-derivate und ihre verwendung in der behandlung von mglur5-rezeptor vermittelten krankheiten
ATE396726T1 (de) Benzothiazole derivate und ihre anwendung in der behandlung von adenosine a2a rezeptor vermittelte krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1928886

Country of ref document: EP